Overview

ValGanciclovir Versus ValAcyclovir for Viral Prophylaxis in Kidney Transplantation

Status:
Completed
Trial end date:
2021-02-28
Target enrollment:
0
Participant gender:
All
Summary
Our study will compare all kidney transplant recipients receiving valganciclovir vs. valacyclovir for one year following kidney transplant and compare: 1. the incidence, magnitude and duration of CMV and EBV viremia in the first year after transplant. 2. the side effects of the anti-viral drugs requiring dose reduction or cessation In addition, we will test renal tissue obtained from any biopsies post-transplant (surveillance or clinically indicated biopsies) by both polymerase chain reaction (PCR) and fluorescence in situ hybridization to assess for latent CMV and/or EBV.
Phase:
Phase 2
Accepts Healthy Volunteers?
No
Details
Lead Sponsor:
University of Minnesota
University of Minnesota - Clinical and Translational Science Institute
Treatments:
Acyclovir
Ganciclovir
Valacyclovir
Valganciclovir
Criteria
Inclusion Criteria:

- All consenting kidney transplant recipients.

Exclusion Criteria:

- Non-consent.

- Recipients with allergies to valacyclovir or valganciclovir

- Recipients that are unable to independently understand the consent form and do not
have a legally authorized representative.